The results of this study suggest that TBIL, PLT and ALB can effectively improve diagnostic efficacy of serum tumor markers for liver cancers but are not the main factors leading to different levels of the diagnostic models between HCC, CCA and benign liver diseases. This evidence concerns the gene ALB and cholangiocarcinoma.